APrevent
APrevent's products improve voice and communication, focusing on the development of a long- term implant system and speech conversion platform for patients with glottic insufficiency and dysarthria.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | $6.0m | Series D | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 33 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
APrevent Medical Inc. is a medical device company that develops solutions for voice and speech disorders. The company's main product is the APrevent Vocal Implant System (VOIS), a long-term implant for patients with glottic insufficiency and unilateral vocal fold paralysis (UVFP). This system is used in a type I thyroplasty procedure to improve vocal fold function.
The VOIS implant has an adjustable cushion that can be modified both during and after surgery, which allows for a standardized surgical procedure. In addition to the implant, APrevent offers Software-as-a-Service (SaaS) technologies to support voice and speech disorder treatments. The company's business model is focused on providing these specialized medical devices and software to ear, nose, and throat (ENT) specialists and hospitals.
APrevent operates in the medical technology market, with a specific focus on the niche of laryngology and voice-related treatments. The company generates revenue through the sale of its VOIS implants and associated software services. APrevent has a presence in both Asia and Europe, with offices in Taiwan and Austria, indicating a strategy for global market penetration.
Keywords: medical devices, vocal implant, speech disorders, ENT, glottic insufficiency, thyroplasty, SaaS, laryngology, medical technology, UVFP